🔗 Share this article

Given that the US proceeds with unprecedented changes to its vaccination recommendations, one figure has surfaced in a surprising turn: Høeg, a US-based sports physician and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccines in the global health crisis and has focused upon alleged deaths following Covid vaccination in her brief time at the Food and Drug Administration.

Scheduled Shifts to Pediatric Vaccine Program

Health officials were set to reveal sweeping revisions to the pediatric vaccine schedule in December, bringing the US with the Danish national calendar, it is understood – a substantial departure that would place the US at odds with much of the global community with insufficient data for benefit. The announcement has been postponed until the new year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to present at the gathering. She was just designated acting director of the FDA’s CDER, the fifth person to lead the office this calendar year.

Consolidating Power at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and biologics divisions as Høeg and Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for ending some childhood immunization guidelines in the US so as to align more like Denmark's approach, a nation with comprehensive healthcare and a population roughly the size of Wisconsin’s.

In her initial statements, she has kept her attention on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Background

Dr. Høeg has no obvious experience in medication creation, approval processes or leadership, which has been standard for previous heads of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“It seems she lacks to have the necessary background” for overseeing the CDER, said a neurologist and psychiatrist. “She’s never run a scientific study. She lacks experience in running a sizeable institution. She lacks background in industry regulation.”

Past heads of CBER would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that prior appointees who led CBER have had.”

This division has an enormous portfolio at the agency, she emphasized.

“Everybody just pays attention on the new drug program, but the off-patent medication office approves a multitude of generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and every single one need to be supervised,” Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial management element to the role, which supervises over 5,000 employees. “It is a massive management job, if you execute it properly,” she said.

Response and Controversial Policies

In response to questions about Høeg’s fitness for the role and whether this assignment represents more teamwork among FDA leaders on vaccines, a representative responded that the “inquiries stem from flawed premises”.

“This background matches the responsibilities of her position,” the representative explained, citing the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial one-day therapy clearance system that allegedly worried her preceding directors. “How are these therapies being picked for this expedited pathway? Who takes the choices?” Howard said. “There is a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent regulations of pharmaceuticals, with the exception of shots.”

Documented Track Record on Vaccines

Regarding vaccines, Høeg has a more established, if troubling, past, some experts observe. She released a analysis using unconfirmed public submissions to assess the rate of heart inflammation after COVID-19 immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccines are more dangerous than they are.

Included in her “policy goals” for the incoming government included altering guidelines for novel immunizations and halting “unnecessary” immunizations, she said after the election on a audio program. At the agency, Høeg has according to sources suggested excluding teenage boys from obtaining COVID-19 vaccinations.

“She’s an all-around dogmatist who commences with her preconceived notions and tailors the evidence to accommodate the evidence in a very deceptive, untruthful manner,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|